Trabectedin Alternatives Compared
| Trabectedin | Votrient (pazopanib) | Pazopanib |
|
|---|
| Trabectedin | Votrient (pazopanib) | Pazopanib |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Soft Tissue Sarcoma. Trabectedin may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Soft Tissue Sarcoma, Renal Cell Carcinoma. Votrient may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Soft Tissue Sarcoma, Renal Cell Carcinoma. Pazopanib may also be used for purposes not listed in this medication guide. |
Related suggestions Soft Tissue Sarcoma
|
|||||||||||||||
| More about Trabectedin | More about Votrient (pazopanib) | More about Pazopanib | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Votrient has an average rating of 8.0 out of 10 from a total of 82 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 9% reported a negative effect. |
Pazopanib has an average rating of 8.0 out of 10 from a total of 92 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 9% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Trabectedin side effects |
View all Votrient side effects |
View all Pazopanib side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
Lower cost generic |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Votrient prices |
View all Pazopanib prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Yondelis |
N/A |
Votrient | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
180 hours |
30.9 hours |
30.9 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category N
Not classified
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 625 drugs are known to interact with Trabectedin:
|
A total of 697 drugs are known to interact with Votrient:
|
A total of 697 drugs are known to interact with Pazopanib:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
October 19, 2009 |
October 19, 2009 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.